Adjuvant therapy with high-dose medroxyprogesterone acetate for operable breast cancer

Breast Cancer

Volumn 6, Issue 2, 1999, Pages 99-107

  Koyama, Hiroki ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Adjuvant therapy; Breast cancer; High dose; Medroxyprogesterone acetate

Indexed keywords

EID: 0242714824     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02966915     Document Type: Article

References (30)

1. Ingle JN, Krook JB, Schaid DJ, et al: Randomized trial in postmenopausal women with node-positive breast cancer; Observation versus adjuvant therapy with cyclophosphamide, 5-fluorouracil, prednisone with or without tamoxifen; Results with seven year median follow-up. In: Salmon SE ed, Adjuvant Therapy of Cancer VI, Saunders, Philadelphia, pp 216-225, 1990.
2. Moliterni A, Bonadonna G, Valagussa P, et al: Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9:1124-1130, 1991.
3. Buzzoni R, Bonadonna G, Valagussa P, et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9:2134-2140, 1991.
4. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 71-85, 1992.
5. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positivenode breast cancer patients aged 50 years and older with tumors responsive to tamoxifen; Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005-1018, 1990. (Pubitemid 20200188)
6. Gárard JP, Héry M, Gedouin D, et al: Postmenopausal patients with node-positive resectable breast cancer; Tamoxifen vs FEC 50 (6 cycles) vs. FEC 50 (6 cycles) plus tamoxifen vs control; Preliminary results of a 4-arm randomised trial. Drugs 45(suppl 2):60-67, 1993. (Pubitemid 23262210)
7. Boccardo F, Rubagotti A, Bruzzi P, et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients; Results of a multicentric Italian study. J Clin Oncol 8:1310-1320, 1990. (Pubitemid 20252302)
8. Bonadonna G, Valagussa P, Brambilla C, et al: Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy. Sent Oncol 18:515-524, 1991.
9. van Veelen H, Willemse PHB, Tjabbes T, et al: Oral high dose medroxyprogesterone acetate versus tamoxifen; A randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer 58:7-13, 1986. (Pubitemid 16093095)
10. Varini M, Cavalli F, Brunner K, et al: High response to high dose medroxyprogesterone acetate (HMPA) does not improve overall survival (OS) of postmeno pts with metastatic breast ca (MBC). Proc ASCO 8:46(abstr 176), 1989.
11. Castiglione-Gertsch M, Pampallona S, Varini M, et al: Primary endocrine therapy for advanced breast cancer; To start with tamoxifen or with medroxyprogesterone acetate? Ann Oncol:735-740, 1993. (Pubitemid 23340083)
12. Rubens RD: Towards improved endocrine therapy for advanced breast cancer. Ann Oncol 4:712-713, 1993. Editorial. (Pubitemid 23340080)
13. Wada T, Koyama H, Takahashi Y, et al: Tamoxifen therapy in locally advanced primary and recurrent breast cancer. J Jap Soc Cancer Ther 14:819-824, 1979. (Pubitemid 10224581)
14. Izuo M, Tominaga T, Yoshida M, et al: Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer; Doubleblind controlled study; Japanese Group for MPA Treatment of Breast Cancer. Jpn J Cancer Clin 31:487-493, 1985.
15. Cavalli F, Goldhirsch A, Jungi F, et al: Randomized trial of low-versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2:414-419, 1984. (Pubitemid 14075970)
16. Yoshida M, Murai H, Miura S: Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer. Jpn J Cancer Chemother 12 (part I):516-523, 1985. (Pubitemid 17213703)
17. Oikawa T, Hiragun A, Yoshida Y, et al: Angiogenic activity of rat mammary carcinomas induced by 7,12-dimethylbenz [a] anthracene and its inhibition by medroxyprogesterone acetate; Possible involvement of antiangiogenic action of medroxyprogesterone acetate in its tumor growth inhibition. Cancer Lett 43:85-92, 1988. (Pubitemid 19007566)
18. Ashino-Fuse H, Takano Y, Oikawa T, et al: Medroxyprogesterone acetate, an anticancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Int J Cancer 44:859-864, 1989. (Pubitemid 20007984)
19. Yamamoto T, Terada N, Nishizawa Y, et al: Angiostatic activities of medroxyprogesterone acetate and its analogues. Int J Cancer 56:393-399, 1994. (Pubitemid 24087635)
20. Pannuti F, Martoni A, Cilenti G, et al: Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients. Eur J Cancer Clin Oncol 24:423-429, 1988. (Pubitemid 18071272)
21. Focan C, Baudoux A, Beauduin M, et al: Adjuvant treatment with high dose medroxyprogesterone acetate in node negative early breast cancer; A 3-year interim report on a randomized trial (I). Acta Oncol 28:237-240, 1989. (Pubitemid 19159633)
22. Yamashita J, Misumi A, Nishimura R, et al: Dose finding study of MPA (high dose medroxyprogesterone acetate) for surgical adjuvant chemoendocrine therapy of breast cancer. Igaku-to-Yakugaku 23:825-830, 1990.
23. Japanese Breast Cancer Society: Reports of the 28th Meeting of the Japanese Breast Cancer Society, Topic I; The results of "Questionnaire concerning disease progression and recurrence of breast cancer." Jpn J Cancer Clin 14:952-959, 1979.
24. Fornander T, Rutgvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer; Occurrence of new primary cancers. Lancet 1:117-120, 1989. (Pubitemid 19034031)
25. Rutqvist LE, Johansson H, Signomklao T, et al: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies; Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645-651, 1995.
26. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients; Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537, 1994. (Pubitemid 24111008)
27. van Leeuwen FE, Benraadt J, Coebergh JWW, et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452, 1994. (Pubitemid 24059587)
28. Stoll BA: Overprolonged adjuvant tamoxifen therapy in breast cancer. Ann Oncol 2:401-403, 1991.
29. Yamamoto H: Controversies in the surgical options for the patient with primary breast cancer. Jpn J Cancer Chemother 21:2720-2227 1994.
30. Focan C, Beauduin M, Lobelle JP, et al: High dose medroxyprogesterone acetate (HD-MPA) adjuvant hormonotherapy for early breast cancer (BC); 5 Years results of a randomized trial. Proc ASCO 9:41(abstr 157), 1990.